<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689804</url>
  </required_header>
  <id_info>
    <org_study_id>AAAP1857</org_study_id>
    <nct_id>NCT02689804</nct_id>
  </id_info>
  <brief_title>EC PK in Women With Normal and Obese BMI</brief_title>
  <official_title>Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A well-designed pharmacokinetics (PK) study may identify the physiologic basis for observed
      differences in levonorgestrel emergency contraception (LNG-EC) and ulipristal acetate
      emergency contraception (UPA-EC) failure rates in women with normal and obese BMI. The
      investigators propose a study to compare serum LNG and UPA levels after administration of a
      single-dose of LNG-EC or UPA-EC. The investigators hypothesize that there will be no
      difference in PK parameters between women with normal BMI and obese women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women will present to the division research office, at which time a history and
      physical exam will be completed. Each participant's BMI will be confirmed and she will be
      assigned to one of two BMI groups (18.5-24.9 versus 30-39.9). At the conclusion of the
      enrollment visit, the research coordinator will randomize each woman to receive a single-dose
      pill of either levonorgestrel 1.5mg (like Plan B One-Step® or its generic formulations) or
      ulipristal acetate 30mg (ellaOne®) on two separate occasions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2015</start_date>
  <completion_date type="Actual">February 3, 2017</completion_date>
  <primary_completion_date type="Actual">December 29, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time 0 to 24 Hours of Serum LNG Concentration</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>LNG-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time 0 to 24 Hours of Serum UPA Concentration</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>UPA-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life of Serum LNG</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(t1/2) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life of Serum UPA</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(t1/2) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of Serum LNG</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(Cl) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of Serum UPA</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(Cl) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of Serum LNG</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(Cmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of Serum UPA</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(Cmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration of Serum LNG</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(Tmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration of Serum UPA</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>(Tmax) calculated in women with normal and obese BMI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Normal-BMI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese-BMI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNG-EC</intervention_name>
    <description>FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg</description>
    <arm_group_label>Normal-BMI</arm_group_label>
    <arm_group_label>Obese-BMI</arm_group_label>
    <other_name>Levonorgestrel (LNG) emergency contraceptive (EC)</other_name>
    <other_name>Next Choice One Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UPA-EC</intervention_name>
    <description>FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg</description>
    <arm_group_label>Normal-BMI</arm_group_label>
    <arm_group_label>Obese-BMI</arm_group_label>
    <other_name>Ulipristal acetate (UPA) emergency contraceptive (EC)</other_name>
    <other_name>ella</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-45 years

          -  English-speaking

          -  BMI 18.5-24.9 kg/m2 or obese BMI 30.0-39.9 kg/m2

          -  Regular menstrual cycles

          -  No use of medroxyprogesterone acetate at least 6 months prior to study enrollment,
             unless resumption of two menstrual cycles

          -  No use of levonorgestrel intrauterine system (levonorgestrel-IUS), etonogestrel
             implant or combined hormonal contraception at least one month prior to the study and
             resumption of one menstrual cycle

          -  Women who are postpartum or post-abortion will be included if they have had at least
             one menstrual cycle since their last pregnancy

        Exclusion Criteria:

          -  Prior allergic reaction to LNG-EC or UPA-EC

          -  Use of hormonal emergency contraception within the past month

          -  Women who are currently pregnant or who are currently breastfeeding

          -  History of cancer other than non-melanoma skin cancer

          -  Medical or surgical conditions or conditions requiring therapies known to impact sex
             steroid production or metabolism

               -  Use of HAART therapy for management of HIV infection

               -  Concomitant use of CYP3A4 inducers like rifampin, barbiturates, carbamazepine,
                  lamotrigine, bosentan, felbamate, griseofulvin, oxcarbazepine, phenytoin, St.
                  John's Wort and topiramate

          -  Current participation in any other trial of an investigational medicine or device in
             the three months leading up to this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn L Westhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Division of Family Planning and Preventive Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piyapa Praditpan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical instructor, Division of Family Planning and Preventive Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, Gainer E, Ulmann A. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011 Oct;84(4):363-7. doi: 10.1016/j.contraception.2011.02.009. Epub 2011 Apr 2.</citation>
    <PMID>21920190</PMID>
  </reference>
  <reference>
    <citation>Kapp N, Abitbol JL, Mathé H, Scherrer B, Guillard H, Gainer E, Ulmann A. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception. 2015 Feb;91(2):97-104. doi: 10.1016/j.contraception.2014.11.001. Epub 2014 Nov 8.</citation>
    <PMID>25528415</PMID>
  </reference>
  <reference>
    <citation>Gemzell-Danielsson K, Kardos L, von Hertzen H. Impact of bodyweight/body mass index on the effectiveness of emergency contraception with levonorgestrel: a pooled-analysis of three randomized controlled trials. Curr Med Res Opin. 2015 Dec;31(12):2241-8. doi: 10.1185/03007995.2015.1094455. Epub 2015 Oct 27.</citation>
    <PMID>26368848</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2017</results_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Carolyn L. Westhoff</investigator_full_name>
    <investigator_title>Director, Division of Family Planning and Preventive Services</investigator_title>
  </responsible_party>
  <keyword>Emergency contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptives, Postcoital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Publication</doc_type>
      <doc_url>http://dx.doi.org/10.1016/j.contraception.2017.01.004</doc_url>
      <doc_comment>Results Reference: Yes</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No significant events in the study that occur after participant enrollment, but prior to assignment of participants to an arm or group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal-BMI</title>
          <description>Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.</description>
        </group>
        <group group_id="P2">
          <title>Obese-MRI</title>
          <description>Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a cross-over study with the same 32 participants receiving each study drug. 34 participants were enrolled into this study but 2 participants discontinued. The final sample includes a total of 16 normal-BMI women and 16 obese-BMI women.</population>
      <group_list>
        <group group_id="B1">
          <title>Normal-BMI</title>
          <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs (LNG-EC and UPA-EC will be given in random order).</description>
        </group>
        <group group_id="B2">
          <title>Obese-BMI</title>
          <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs (LNG-EC and UPA-EC will be given in random order).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" lower_limit="19" upper_limit="35"/>
                    <measurement group_id="B2" value="32.3" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B3" value="30" lower_limit="19" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time 0 to 24 Hours of Serum LNG Concentration</title>
        <description>LNG-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-BMI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to 24 Hours of Serum LNG Concentration</title>
          <description>LNG-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women.</description>
          <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.5" lower_limit="171.4" upper_limit="245.6"/>
                    <measurement group_id="O2" value="100.8" lower_limit="82.9" upper_limit="118.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time 0 to 24 Hours of Serum UPA Concentration</title>
        <description>UPA-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women.</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-BMI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to 24 Hours of Serum UPA Concentration</title>
          <description>UPA-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women.</description>
          <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.5" lower_limit="237.3" upper_limit="349.8"/>
                    <measurement group_id="O2" value="362.5" lower_limit="230.9" upper_limit="494.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life of Serum LNG</title>
        <description>(t1/2) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-BMI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life of Serum LNG</title>
          <description>(t1/2) calculated in women with normal and obese BMI</description>
          <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="22.2" upper_limit="31.8"/>
                    <measurement group_id="O2" value="50.4" lower_limit="44.6" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life of Serum UPA</title>
        <description>(t1/2) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-MRI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life of Serum UPA</title>
          <description>(t1/2) calculated in women with normal and obese BMI</description>
          <population>Cross-over study: 16 normal-BMI and 16 obese-BMI enrolled and each participant received both drugs in random order.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" lower_limit="24.0" upper_limit="45.8"/>
                    <measurement group_id="O2" value="65.9" lower_limit="50.8" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance of Serum LNG</title>
        <description>(Cl) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-MRI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of Serum LNG</title>
          <description>(Cl) calculated in women with normal and obese BMI</description>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.8" upper_limit="5.8"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.3" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance of Serum UPA</title>
        <description>(Cl) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-MRI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of Serum UPA</title>
          <description>(Cl) calculated in women with normal and obese BMI</description>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.2" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.8" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration of Serum LNG</title>
        <description>(Cmax) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-MRI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration of Serum LNG</title>
          <description>(Cmax) calculated in women with normal and obese BMI</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="14.0" upper_limit="22.4"/>
                    <measurement group_id="O2" value="10.8" lower_limit="6.8" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration of Serum UPA</title>
        <description>(Cmax) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-MRI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration of Serum UPA</title>
          <description>(Cmax) calculated in women with normal and obese BMI</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="57.4" upper_limit="121.2"/>
                    <measurement group_id="O2" value="95.6" lower_limit="65.8" upper_limit="125.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration of Serum LNG</title>
        <description>(Tmax) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-MRI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration of Serum LNG</title>
          <description>(Tmax) calculated in women with normal and obese BMI</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.0"/>
                    <measurement group_id="O2" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration of Serum UPA</title>
        <description>(Tmax) calculated in women with normal and obese BMI</description>
        <time_frame>Up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal-BMI</title>
            <description>Women with normal BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
          <group group_id="O2">
            <title>Obese-MRI</title>
            <description>Women with obese BMI will receive the first EC dose and complete PK assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs LNG-EC and UPA-EC will be given in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration of Serum UPA</title>
          <description>(Tmax) calculated in women with normal and obese BMI</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.0"/>
                    <measurement group_id="O2" value="1.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>The Total Number of Participants at Risk is not consistent with numbers provided in the rows in the Participant Flow module. There were 16 participants classified as &quot;Normal-BMI&quot; and 16 participants classified as &quot;Obese-BMI&quot;, and all participants received all interventions; however, PRS instructed for the investigator to further split the 2 BMI arms into the time period when &quot;Normal&quot; and &quot;Obese-BMI&quot; received each drug, so that the reported events can be attributed to the appropriate drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Normal-BMI on LNG</title>
          <description>Women with normal BMI will receive LNG-EC</description>
        </group>
        <group group_id="E2">
          <title>Normal-BMI on UPA</title>
          <description>Women with obese BMI will receive UPA-EC</description>
        </group>
        <group group_id="E3">
          <title>Obese-BMI on LNG</title>
          <description>Women with obese BMI will receive LNG-EC</description>
        </group>
        <group group_id="E4">
          <title>Obese-BMI on UPA</title>
          <description>Women with obese BMI will receive UPA-EC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lower abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carolyn L. Westhoff, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-4805</phone>
      <email>clw3@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

